Literature DB >> 2024972

Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams.

F Serour1, M Dan, A Gorea, A Yellin, Y Lieberman, S A Berger.   

Abstract

The penetration of ofloxacin into lung tissue was studied in 10 patients subjected to pulmonary surgery. Samples of blood and lung tissue were obtained 3 to 8 h (mean, 5 h) after oral administration of 200 mg. The mean level in tissue was 2.17 +/- 0.5 micrograms/g, while the mean level in serum was 0.85 +/- 0.23 micrograms/ml. The mean lung tissue/serum concentration ratio was 2.55 +/- 0.30. The achievable levels of ofloxacin in lung tissue are above the MICs for most pulmonary pathogens.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2024972      PMCID： PMC245011          DOI： 10.1128/AAC.35.2.380

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 2.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

3.  The penetration of ofloxacin into lung tissue.

Authors:  W J Wijnands; T B Vree; A M Baars; J C Hafkenscheid; B E Kohler; C L van Herwaarden
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

4.  Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.

Authors:  W J Wijnands; T B Vree; A M Baars; C L van Herwaarden
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

5.  Diffusion of ofloxacin into human lung tissue.

Authors:  L Couraud; J B Fourtillan; M C Saux; A Bryskier; M Vincent du Laurier
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Comparative pharmacokinetics of new quinolones.

Authors:  H Lode; G Höffken; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reimnitz; K Borner; P Koeppe
Journal:  Drugs       Date:  1987       Impact factor: 9.546
  6 in total
  5 in total

1.  Penetration of orally administered prulifloxacin into human lung tissue.

Authors:  Ercole Concia; Benedetta Allegranzi; Giovanni B Ciottoli; Giovanna Orticelli; Marcello Marchetti; Paolo Dionisio
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.